首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備呼吸器

市場調查報告書

商品編碼

1374806

全球數位劑量吸入器市場 -2023-2030

Global Digital Dose Inhalers Market -2023-2030

出版日期: 2023年11月01日 | 出版商:

DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

數位劑量吸入器是一種呼吸輔助設備，可以與電子設備連接以每天檢查患者的健康狀況。這些對於患有氣喘或阻塞性疾病等呼吸道疾病的人特別有幫助。這些吸入器中的感測器會提示使用者每天在適當的時間服藥。

數位劑量吸入器健康系統使用機電感測器和微電子技術來監測吸入器的驅動。一些小工具包括連結的智慧型手機、與患者通訊的行動應用程式、雲端伺服器以及供醫生查看儀表板資料的入口網站。

一些數位劑量吸入器可以測量污染或花粉水平，或在患者忘記時發出警報。智慧吸入器會通知患者漏服或重複服藥，並提醒他們按時、自動、輕鬆地服藥。

市場動態：促進因素與限制因素

呼吸道疾病盛行率上升

呼吸道疾病盛行率的上升是預測期內幫助市場成長的關鍵促進因素之一。由於哮喘和慢性阻塞性肺病等呼吸系統疾病的增加，數位劑量吸入器設備的使用經常被迅速使用，這確實會促進市場成長。

例如，根據疾病管制與預防中心的數據，慢性阻塞性肺病估計影響 2 億人，每年有 320 萬人死亡，使其成為全球第三大死因。

氣喘是最常見的非傳染性疾病之一，影響全球 2.62 億人。預計到 2022 年，肺癌新病例將接近 220 萬，死亡人數將達 180 萬，肺癌佔全球癌症死亡人數的四分之一。下呼吸道感染或肺炎是重要的死亡原因，每年造成超過 240 萬人死亡，主要發生在低收入和中等收入國家 (LMIC)。 COVID-19 顯著增加了全球肺炎死亡人數。

此外，吸入器技術進步、數據驅動的醫療保健、老年人口盛行率的上升以及遠距醫療等的成長將在預測期內進一步推動市場。

市場動態：克制

許多限制因素阻礙了預測期內的市場成長，其中包括藥物成本增加和與設備相關的高成本、隱私和資料安全問題、監管障礙以及人們對氣喘的先進治療和設備缺乏認知將阻礙市場成長。

Digital dose inhalers are breathing aids that can be linked to electronic devices to check on a patient's health every day. These are especially helpful for people with respiratory diseases like asthma or obstructive diseases. Sensors in these inhalers prompt the user to take medicine at the appropriate times each day.

Digital dose inhaler health systems use electromechanical sensors and microelectronics to monitor inhaler actuation. Some gadgets include a linked smartphone, a mobile app that communicates with the patient, a cloud server, and a portal for the physician to see dashboard data.

Some digital dose inhalers can measure pollution or pollen levels or alarm patients if they forget them. Smart inhalers notify patients of missed or repeated doses and remind them to take their dosages on time, automatically, and easily.

Market Dynamics: Drivers and Restraints

Rise in prevalence of respiratory diseases

The rise in the prevalence of respiratory disease is one of the key drivers that helps the market to grow during the forecast period. Since the rise in respiratory diseases like asthma and COPD the use of digital dose inhaler devices is often used rapidly which indeed will increase the market growth.

For instance, according to the Centers for Disease Control and Prevention COPD affects an estimated 200 million people, with 3.2 million dying each year, making it the third-leading cause of mortality globally.

Asthma is one of the most common noncommunicable illnesses, impacting 262 million people worldwide. With almost 2.2 million new instances of lung cancer expected in 2022 and 1.80 million fatalities, lung cancer accounts for one in every four cancer deaths worldwide. Lower respiratory tract infection or pneumonia is a prominent cause of death, accounting for more than 2.4 million fatalities each year, primarily in low and middle-income countries (LMICs). COVID-19 has significantly increased pneumonia fatalities worldwide.

Furthermore, technological advancements in technological advancements in inhalers, Data-Driven Healthcare, the rise in the prevalence of the geriatric population, and rise in the telemedicine's and others will further drive the market during the forecast period.

Market Dynamics: Restraint

Many restraint factors hampers the market growth during the forecast period some of the mare like, increasing medication cost and high cost associated with devices, privacy and data security concerns, regulatory hurdles, and lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.

Segment Analysis

The global digital dose inhalers is segmented based on product type, type, application, type, distribution channel and region.

The metered-dose inhaler from the device type segment accounted for approximately 41.2% of the market share

The metered-dose inhaler from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A metered-dose inhaler has a pressurized canister of medication that fits into a mouthpiece. In most instances, a dose of medication is released into your lungs by pushing the canister into the mouthpiece. Another type releases medication automatically when you inhale. Some metered-dose inhalers have counters that track how many doses remain.

For instance, on July 2023, Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, stated that they have been launched Luforbec 100/6 (beclometasone 100µg / for motel 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.

Moreover, on February 8 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, stated the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.

HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, Cystic Fibrosis and other respiratory conditions caused by COVID-19, to track their usage and facilitate improved adherence to their prescribed therapy.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years.

For instance, in September 2020, Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.

COVID-19 Impact Analysis

COVID-19 had a substantial impact on the global digital dose inhalers market importantly on asthma for instance, according to the article titled "Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a National Incident Cohort Study" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are raising the cases of respiratory disorders which generates the need for digital dose inhalers.

Competitive Landscape

The major global players in the digital dose inhalers market include: Novartis International AG, Propeller Health, H&T Presspart Manufacturing Ltd, AptarGroup Inc, Amiko Digital Health Limited, Trudell Medical UK Limited, ReciPharm, Sensirion, Teva Pharmaceuticals, Cohero Health, Inc and among others.

Key Developments

In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
In October 2020, Zydus launched a pressurised Metered Dose Inhaler for COPD patient.

Why Purchase the Report?

To visualize the global digital dose inhalers market segmentation-based device type, application, type, distribution channel and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of digital dose inhalers market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global digital dose inhalers market report would provide approximately 69 tables, 70 figures, and 185 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Device Type
3.2. Snippet by Application
3.3. Snippet by Type
3.4. Snippet by Distribution Channel
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Driver
  - 4.1.1.1. Rise in the prevalence of respiratory diseases
  - 4.1.1.2. Rise in the technology advancements
- 4.1.2. Restraints
  - 4.1.2.1. Security issues
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Device Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 7.1.2. Market Attractiveness Index, By Device Type
7.2. Metered Dose Inhalers *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Dry Powder Inhalers

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Asthma *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. COPD
8.4. Others

9. By Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Type
9.2. Branded *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Generic

10. By Distribution Channel

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospital Pharmacies *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. UK
  - 11.3.7.3. France
  - 11.3.7.4. Italy
  - 11.3.7.5. Spain
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Novartis International AG
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Propeller Health
13.3. H&T Presspart Manufacturing Ltd
13.4. AptarGroup Inc
13.5. Amiko Digital Health Limited
13.6. Trudell Medical UK Limited
13.7. ReciPharm
13.8. Sensirion
13.9. Teva Pharmaceuticals
13.10. Cohero Health, Inc

LIST NOT EXHAUSTIVE